Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023 

Rhea-AI Summary

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology firm, will showcase preclinical data on SRF114, its anti-CCR8 antibody, at the AACR Annual Meeting 2023, scheduled for April 14-19, 2023, in Orlando, FL.

The poster, titled "Depletion of CCR8+ tumor Treg cells with SRF114 or anti-CCR8 therapy promotes robust antitumor activity and reshapes the tumor microenvironment toward a more pro-inflammatory milieu", will cover significant findings such as SRF114's ability to reduce tumor growth in murine models.

The session is set for April 18, 2023, from 1:30 p.m. to 5:00 p.m. ET.

CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will present a poster highlighting new preclinical data for SRF114, the company’s fully human, afucosylated anti-CCR8 antibody, at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14-19, 2023, in Orlando, Fl.

Details on the poster presentation are below:

Title: Depletion of CCR8+ tumor Treg cells with SRF114 or anti-CCR8 therapy promotes robust antitumor activity and reshapes the tumor microenvironment toward a more pro-inflammatory milieu
Abstract number: 5125
Session category: Immunology
Session title: Combination Immunotherapies 2
Session date and time: Tuesday April 18, 2023, from 1:30 p.m. to 5:00 p.m. ET

A copy of the poster will be available on the Posters & Publications page of the company’s website following the meeting.

About SRF114

SRF114 is a fully human, afucosylated anti-CCR8 antibody designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment. In preclinical studies, Surface Oncology has shown that SRF114 induces antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) pathways to deplete intratumoral Treg cells. In addition, SRF114 reduced tumor growth in murine models. These findings support the advancement of SRF114 as a therapeutic candidate that holds the potential to drive anti-tumor immunity in patients.

About Surface Oncology

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned programs; SRF388, a Phase 2 program which targets IL-27, and SRF114 which selectively depletes regulatory T cells in the tumor microenvironment via targeting CCR8. In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s novel, investigational cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.

Contact

Scott Young
(617) 865-3250
syoung@surfaceoncology.com

FAQ

What is the poster presentation by Surface Oncology about at AACR Annual Meeting 2023?

The poster presentation focuses on new preclinical data for SRF114, highlighting its ability to deplete CCR8+ tumor Treg cells and promote antitumor activity.

When will Surface Oncology present its data on SRF114?

Surface Oncology will present its data on SRF114 on April 18, 2023, from 1:30 p.m. to 5:00 p.m. ET.

What is SRF114's mechanism of action?

SRF114 is designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment, enhancing antitumor immunity.

Where is the AACR Annual Meeting 2023 taking place?

The AACR Annual Meeting 2023 will be held in Orlando, Florida.

What is the significance of the data presented on SRF114?

The data suggests that SRF114 can induce pathways that deplete intratumoral Treg cells, potentially leading to reduced tumor growth and enhanced immune response.